Highest-materiality recent filing
Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events
First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.
Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares
Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.
Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study
Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001
100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries
Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.
BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings
Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.
Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan
Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt
Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.
Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged
JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
Board designated 49.5M of 50M authorized preferred shares as Convertible Preferred Stock with 10 votes per share on as-converted basis.
Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19
FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.
Bioxytran secures $500k equity investment from Triton Funds for COVID-19 trial funding
Triton Funds LP to purchase 1,612,903 shares at $0.31/share, totaling $500,000.
Board dismissed Pinnacle Accountancy Group and engaged BF Borgers CPA PC as independent auditor, effective March 6, 2023.
Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial
India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.
Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients
IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.
Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients
100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.
Bioxytran modifies officer severance terms after $1.27M salary forfeiture
Officers forfeited $1,273,000 in accrued salaries and benefits on Aug 1, 2022.
Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials
Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.
Bioxytran publishes positive peer-reviewed data for ProLectin-M and PLG-007 drug candidates
August 1, 2022 article in Int. J. Health Sciences: ProLectin-M blocks SARS-CoV-2 in vitro; all 5 COVID-19 patients achieved complete remission, zero hospitalization.
Effective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased).
Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.
The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.
Max materiality 0.90 · Median 0.60 · Most common event other_material